- Home
- ALLY vs EXEL Comparison
ALLY vs EXEL Comparison
Compare ALLY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALLY | EXEL |
|---|---|---|
| Founded | 1919 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 11.1B |
| IPO Year | 2014 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ALLY | EXEL |
|---|---|---|
| Price | $42.69 | $44.37 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 24 |
| Target Price | ★ $46.33 | $44.73 |
| AVG Volume (30 Days) | ★ 2.7M | 2.5M |
| Earning Date | 01-21-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | 11.52 | ★ 53.55 |
| EPS | 1.67 | ★ 2.38 |
| Revenue | ★ $7,171,000,000.00 | $2,288,218,000.00 |
| Revenue This Year | $20.26 | $9.14 |
| Revenue Next Year | $14.12 | $12.51 |
| P/E Ratio | $25.36 | ★ $18.67 |
| Revenue Growth | 6.02 | ★ 9.93 |
| 52 Week Low | $29.52 | $31.90 |
| 52 Week High | $44.83 | $49.62 |
Technical Indicators
Market Signals| Indicator | ALLY | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 63.52 |
| Support Level | $37.51 | $43.00 |
| Resistance Level | $41.77 | $44.79 |
| Average True Range (ATR) | 1.03 | 1.03 |
| MACD | 0.39 | 0.06 |
| Stochastic Oscillator | 93.52 | 83.48 |
Price Performance
Historical ComparisonAbout ALLY Ally Financial Inc.
Formerly the captive financial arm of General Motors, Ally Financial became an independent publicly traded firm in 2014 and is one of the largest consumer auto lenders in the country. While the firm has expanded its product offerings over time, it remains primarily focused on auto lending, with more than 70% of its loan book in consumer auto loans and dealer financing. Ally also offers auto insurance, commercial loans, credit cards, and holds a portfolio of mortgage debt, giving the bank a diversified business model, which includes brokerage services.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.